CIK 0001984086 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Septerna, Inc.
Sign in to watch- Ticker
- SEPN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 843891440
- Phone
- 650-338-3533
- Business address
- 250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,210,085
- in 3 filings, $4.2M under 10b5-1 plans
Net −$4,210,085. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-02 | Shaikhly Samira Chief People Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −11,638 | 3,460 | ||
| 2026-03-02 | Shaikhly Samira Chief People Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,101 | 5,101 | ||
| 2026-02-18 | Bhatt Elizabeth President and COO | Option exercise 10b5-1 | +4,000 | $6.81 | $27K | 178,209 |
| 2026-02-18 | Bhatt Elizabeth President and COO | Sale 10b5-1 | −2,200 | $28.46 | $63K | 176,009 |
| 2026-02-18 | Bhatt Elizabeth President and COO | Sale 10b5-1 | −1,800 | $29.58 | $53K | 174,209 |
| 2026-02-18 | Bhatt Elizabeth President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,000 | 88,911 | ||
| 2026-02-06 | Long Daniel D. SVP, Drug Discovery | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2026-02-06 | Klein Uwe SVP, Biological Sciences | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2026-02-06 | Shaikhly Samira Chief People Officer | Grant or award · Stock Option (Right to Buy) | +80,000 | 80,000 | ||
| 2026-02-06 | Labrucherie Gil M Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2026-02-06 | Kim Jae B. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2026-02-06 | Bhatt Elizabeth President and COO | Grant or award · Stock Option (Right to Buy) | +155,000 | 155,000 | ||
| 2026-02-06 | Finer Jeffrey Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +400,000 | 400,000 | ||
| 2026-02-06 | Wilson Mark Andrew Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +165,000 | 165,000 | ||
| 2025-11-10 | Long Daniel D. SVP, Drug Discovery | Sale | −3,501 | $18.06 | $63K | 92,911 |
| 2025-09-25 | Gottesdiener Keith Michael Director | Grant or award · Stock Option (Right to Buy) | +33,246 | 33,246 | ||
| 2025-08-18 | Klein Uwe SVP, Biological Sciences | Option exercise | +10,452 | $2.76 | $29K | 10,452 |
| 2025-08-18 | Klein Uwe SVP, Biological Sciences | Option exercise | +4,935 | $2.76 | $14K | 15,387 |
| 2025-08-18 | Klein Uwe SVP, Biological Sciences | Option exercise | +7,621 | $6.81 | $52K | 23,008 |
| 2025-08-18 | Klein Uwe SVP, Biological Sciences | Option exercise · Stock Option (Right to Buy) | −10,452 | 10,453 |
Page 5 of 8 · 148 trades